Aurinia Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved its Lupkynis (voclosporin) treatment for use in adult patients with …
Shares in Aurinia Pharmaceuticals (AUPH) tanked 10% after-hours after the biopharma announced disappointing topline data from the Phase 2/3 Audrey clinical study evaluating …
Shares in Aurinia Pharma (AUPH) surged 9% in Tuesday’s extended trading after the U.S.
Shares in Aurinia Pharmaceuticals, Inc (AUPH) advanced in pre-market trading as the biotech company announced the submission of the New Drug Application (NDA) …
Finding a stock which will deliver enormous returns is the Street’s holy grail. Upon first glance, this task may seem rather simple.
2019 has not been a great year to own biotech stocks (so far). Since the year began, the Nasdaq Biotechnology Index (NBI) is …
Aurinia (AUPH) investors got cold feet today, sending shares tumbling nearly 9%. The reason?
This morning, Aurinia (AUPH) presented at the Cantor 4th Annual Healthcare Conference in New York City, and provided a corporate overview of its clinical …
Cantor analyst Elemer Piros is out with a short research note on shares of Aurinia Pharmaceuticals (NASDAQ:AUPH), following the company’s first-quarter financial results and update on …
Aurinia potentially has the 1st treatment for lupus nephritis, says RBC Capital’s Douglas Miehm.